• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Pharma
    • Vaccines
    • Asia
    • Cell & Gene Therapy
    • Drug Delivery
    • Executives
  • Manufacturing
    • Facilities
    • Recalls
    • Warning Letters
  • Marketing
  • Special Reports
  • Fierce 50
    • Special Report
    • Awards Gala
  • Trending
    • Oncology
    • Supply Chain
    • AI and Machine Learning
  • Awards
    • Outsourcing Awards
    • Innovation Awards
    • Pharma Marketing Awards
  • Resources
    • Podcasts
    • Fierce Events
    • Industry Events
    • Webinars
    • Whitepapers
    • Survey
  • Events
  • Subscribe
Home
Subscribe
Hamburger Menu Hamburger Menu
  • Pharma
    • Vaccines
    • Asia
    • Cell & Gene Therapy
    • Drug Delivery
    • Executives
  • Manufacturing
    • Facilities
    • Recalls
    • Warning Letters
  • Marketing
  • Special Reports
  • Fierce 50
    • Special Report
    • Awards Gala
  • Trending
    • Oncology
    • Supply Chain
    • AI and Machine Learning
  • Awards
    • Outsourcing Awards
    • Innovation Awards
    • Pharma Marketing Awards
  • Resources
    • Podcasts
    • Fierce Events
    • Industry Events
    • Webinars
    • Whitepapers
    • Survey
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
IPO initial public offering
Favicon Fierce Biotech

Avalyn brings in $300M from oversized IPO

Avalyn overshot its expectations with a $300 million IPO that the biotech will use to fund late-stage studies of its reformulated respiratory drugs.
James Waldron Apr 30, 2026 3:18am
Red and white pawns with golden arrows Employee swap or turnover concept

Drugmaker’s reputations shift amid political pressures: survey

Apr 30, 2026 1:00am
Astellas

Lessons from the eye: How cell therapy is shaping the future of regenerative medicine

Brought to you by ASTELLAS
Soriot

AstraZeneca CEO outlines conservative forecast model for MFN

Apr 29, 2026 3:08pm
AbbVie

AbbVie shrugs off new J&J competition for fast-growing Skyrizi

Apr 29, 2026 2:53pm
Teva

Teva's innovative drugs helped carry strong Q1

Apr 29, 2026 2:27pm
More News

Regeneron sees more regulatory issues, sales declines for Eylea

Apr 29, 2026 12:05pm

Shingrix surge, Exdensur flop highlight GSK CEO’s first quarter

Apr 29, 2026 10:47am

Pfizer looks to jump start Elrexfio with topline win

Apr 29, 2026 10:16am

Chiesi grows rare disease ambitions with $1.9B KalVista buyout

Apr 29, 2026 10:01am
Home
  • Connect
    • The Team
    • Advertise
    • Marketing Kit
    • Let's Talk
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Biotech
    • Fierce Healthcare
    • Fierce Pharma
  • Our Events
    • Life Sciences Events
©2026 Questex LLC All rights reserved.
Terms of use
Privacy Policy
Privacy Settings